Remission predictors during treatment with genetically engineered biological preparations in patients with juvenile idiopathic arthritis without...
Алексеева Е. И., Дворяковская Т. М., Исаева К. Б., Денисова Р. В., Фетисова А. Н., Ванкова Д. Д., Алшевскайа А. А., Москалев А. В., Мамутова А. В.
Педиатрия. Журнал им. Г.Н. Сперанского
Т. 98, Вып. 3, С. 60-66
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.24110/0031-403X-2019-98-3-60-66
Аннотация:
Target influence on development mechanisms of juvenile idiopathic arthritis (JIA) allowed genetically engineered biological preparations (GEBP) to control previously resistant forms of the disease, however even now 30[%] of patients have no clinical response. The identification of prognostic response factors to GEBP therapy can provide an individual approach in the treatment of patients with JIA. Objective of the research: To develop an algorithm for personalized GEBP therapy with different action mechanism in patients with JIA without systemic manifestations, considering predictors of response to biological therapy. Materials and methods: Results of treatment of 506 patients with JIA without systemic manifestations, treated with etanercept from December 2009 to August 2014, adalimumab from August 2008 to August 2014, tocilizumab from July 2009 to August 2017. The relationship of the initial and registered clinical and laboratory parameters after 1 month of treatment with remission accor
Ключевые слова:
Adalimumab; Children; Etanercept; Juvenile idiopathic arthritis; Predictors; Tocilizumab
adalimumab; etanercept; interleukin 6 receptor; tocilizumab; algorithm; arthritis; Article; biological therapy; disease duration; genetic engineering; genetically engineered biological preparation; human; juvenile rheumatoid arthritis; major clinical study; predictor variable; remission; uveitis
Язык текста: Русский
ISSN: 1990-2182
Алексеева Е. И. Екатерина Иосифовна 1962-
Дворяковская Т. М. Татьяна Маратовна 1975-
Исаева К. Б.
Денисова Р. В.
Фетисова А. Н.
Ванкова Д. Д.
Алшевскайа А. А.
Москалев А. В.
Мамутова А. В.
Alekseeva E. I. Ekaterina Iosifovna 1962-
Dvoryakovskaya T. M. Tat`yana Maratovna 1975-
Isaeva K. B.
Denisova R. V.
Fetisova A. N.
Vankova D. D.
Alshevskaya A. A.
Moskalev A. V.
Mamutova A. V.
Remission predictors during treatment with genetically engineered biological preparations in patients with juvenile idiopathic arthritis without systemic manifestations
Remission predictors during treatment with genetically engineered biological preparations in patients with juvenile idiopathic arthritis without...
Текст визуальный непосредственный
Педиатрия. Журнал им. Г.Н. Сперанского
ООО "Педиатрия"
Т. 98, Вып. 3 С. 60-66
2019
Статья
Adalimumab Children Etanercept Juvenile idiopathic arthritis Predictors Tocilizumab
adalimumab etanercept interleukin 6 receptor tocilizumab algorithm arthritis Article biological therapy disease duration genetic engineering genetically engineered biological preparation human juvenile rheumatoid arthritis major clinical study predictor variable remission uveitis
Target influence on development mechanisms of juvenile idiopathic arthritis (JIA) allowed genetically engineered biological preparations (GEBP) to control previously resistant forms of the disease, however even now 30[%] of patients have no clinical response. The identification of prognostic response factors to GEBP therapy can provide an individual approach in the treatment of patients with JIA. Objective of the research: To develop an algorithm for personalized GEBP therapy with different action mechanism in patients with JIA without systemic manifestations, considering predictors of response to biological therapy. Materials and methods: Results of treatment of 506 patients with JIA without systemic manifestations, treated with etanercept from December 2009 to August 2014, adalimumab from August 2008 to August 2014, tocilizumab from July 2009 to August 2017. The relationship of the initial and registered clinical and laboratory parameters after 1 month of treatment with remission accor